Acasti Pharma Inc. (ACST) and Odonate Therapeutics Inc. (NASDAQ:ODT) Comparison side by side

As Biotechnology businesses, Acasti Pharma Inc. (NASDAQ:ACST) and Odonate Therapeutics Inc. (NASDAQ:ODT), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acasti Pharma Inc. 1 0.00 N/A -1.22 0.00
Odonate Therapeutics Inc. 27 0.00 N/A -4.46 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Acasti Pharma Inc. and Odonate Therapeutics Inc.

Profitability

Table 2 represents Acasti Pharma Inc. (NASDAQ:ACST) and Odonate Therapeutics Inc. (NASDAQ:ODT)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Acasti Pharma Inc. 0.00% 0% 0%
Odonate Therapeutics Inc. 0.00% -78% -68.4%

Analyst Recommendations

Recommendations and Ratings for Acasti Pharma Inc. and Odonate Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acasti Pharma Inc. 0 0 1 3.00
Odonate Therapeutics Inc. 1 0 0 1.00

Acasti Pharma Inc.’s upside potential is 262.15% at a $7.75 average price target. Competitively Odonate Therapeutics Inc. has a consensus price target of $10, with potential downside of -64.74%. The results from earlier shows that analysts view suggest that Acasti Pharma Inc. seems more appealing than Odonate Therapeutics Inc.

Institutional & Insider Ownership

Roughly 4.02% of Acasti Pharma Inc. shares are held by institutional investors while 83.5% of Odonate Therapeutics Inc. are owned by institutional investors. Acasti Pharma Inc.’s share held by insiders are 13.28%. On the other hand, insiders held about 0.1% of Odonate Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acasti Pharma Inc. 2.99% 107.76% 181.87% 129.52% 338.18% 189.7%
Odonate Therapeutics Inc. 21.28% 8.9% 135.96% 150.77% 100.89% 189.42%

For the past year Acasti Pharma Inc. was more bullish than Odonate Therapeutics Inc.

Summary

Acasti Pharma Inc. beats Odonate Therapeutics Inc. on 6 of the 8 factors.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.